General Information

We are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing our patented piezo-print technology to deliver micro-therapeutics topically to the eye. This micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers that deliver 30–50 µL) that routinely overdose or under-dose when used in the topical administration of ophthalmic therapeutics.

Employees: 7
Founded: 2014
Contact Information
Address 501 Fifth Avenue, Suite 1404, New York, NY 10017, US
Phone Number 917-289-1117
Web Address http://www.eyenovialab.com
View Prospectus: Eyenovia
Financial Information
Market Cap $99.4mil
Revenues $0 mil (last 12 months)
Net Income $-4.1 mil (last 12 months)
IPO Profile
Symbol EYEN
Exchange NASDAQ
Shares (millions): 2.7
Price range $10.00 - $10.00
Est. $ Volume $27.3 mil
Manager / Joint Managers Ladenburg Thalmann/ Roth Capital Partners​
CO-Managers -
Expected To Trade: 1/25/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change